December 10, 2012

HELIX BIOPHARMA CORP. ANNOUNCES SALE OF RIVEX PHARMA DIVISION TO PHARMASCIENCE INC. (PDF)

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has entered into a definitive agreement for the sale of its Rivex Pharma division to Pharmascience Inc. (“Pharmascience”) for gross cash proceeds of up to $8.5 million (the “Rivex Transaction”). The proceeds from the sale would provide a significant infusion of cash to Helix, which Helix will use to fund its ongoing research and development and other operating activities.